

(FILE 'HOME' ENTERED AT 16:11:31 ON 24 JUN 2003)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 16:11:42 ON 24 JUN 2003

L1 686 S TOXIN A REPEATING UNITS OR (ARU)
L2 19171 S CLOSTRIDIUM DIFFICILE
L3 3713 S L2 AND TOXIN A
L4 265952 S POLYSACCHARIDE OR LIPOPOLYSACCHARIDE
L5 533578 S (CONJUGATED OR CONJUGATE OR CONJUGATES)
L6 21055 S L4 AND L5
L7 69 S L6 AND L3
L8 7 S L6 AND L1 AND L2
L9 64 DUP REM L7 (5 DUPLICATES REMOVED)
L10 2 DUP REM L8 (5 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 16:22:47 ON 24 JUN 2003

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 16:36:58 ON 24 JUN 2003

L11 322 S (RARU) OR RECOMBINANT TOXIN A REPEATING UNITS
L12 10 S L11 AND CARRIER
L13 5 DUP REM L12 (5 DUPLICATES REMOVED)

FILE 'AGRICOLA, LIFESCI, CONFSCI, BIOSIS, VETU, VETB, PHIN, PHIC' ENTERED AT 16:41:06 ON 24 JUN 2003

L14 196 S RARU OR RECOMBINANT TOXIN A REPEATING UNITS
L15 3 S L14 AND CARRIER
L16 3 S L14 AND VACCINE
L17 1 S L16 AND ?SACCHARIDE
L18 2 S L14 AND (CONJUGATE OR CONJUGATED OR CONJUGATES)
L19 3 S L14 AND (FUSION OR HYBID OR CHIMERIC OR FUSED)

=>

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH,
USPATFULL, JAPIO' ENTERED AT 16:36:58 ON 24 JUN 2003

L11 322 S (RARU) OR RECOMBINANT TOXIN A REPEATING UNITS
L12 10 S L11 AND CARRIER
L13 5 DUP REM L12 (5 DUPLICATES REMOVED)

=>

(FILE 'HOME' ENTERED AT 16:11:31 ON 24 JUN 2003)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH,
USPATFULL, JAPIO' ENTERED AT 16:11:42 ON 24 JUN 2003

L1	686 S TOXIN A REPEATING UNITS OR (ARU)
L2	19171 S CLOSTRIDIUM DIFFICILE
L3	3713 S L2 AND TOXIN A
L4	265952 S POLYSACCHARIDE OR LIPOPOLYSACCHARIDE
L5	533578 S (CONJUGATED OR CONJUGATE OR CONJUGATES)
L6	21055 S L4 AND L5
L7	69 S L6 AND L3
L8	7 S L6 AND L1 AND L2
L9	64 DUP REM L7 (5 DUPLICATES REMOVED)
L10	2 DUP REM L8 (5 DUPLICATES REMOVED)

L9 ANSWER 1 OF 64 USPATFULL

AB The present invention provides novel polynucleotides encoding K+betaM3 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+betaM3 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

AN 2003:166513 USPATFULL

TI Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM3

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
Ryseck, Rolf-Peter, Ewing, NJ, UNITED STATES
Watson, Andrew J., West Windsor, NJ, UNITED STATES
Carroll, Pamela, Princeton, NJ, UNITED STATES

PI US 2003114371 A1 20030619

AI US 2002-71458 A1 20020207 (10)

PRAI US 2001-267039P 20010207 (60)

US 2001-281224P 20010403 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 13661

L9 ANSWER 2 OF 64 USPATFULL

AB The present invention provides isolated polypeptides comprising an amino acid sequence of a choline binding protein CbpG. This invention provides an isolated polypeptide comprising an amino acid sequence of a choline binding polypeptide CbpG or N-terminal CbpG truncate, including analogs, variants, mutants, derivatives and fragments thereof. This invention further provides an isolated immunogenic polypeptide comprising an amino acid sequence of a choline binding protein CbpG. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a choline binding protein CbpG. This invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids. Assays for compounds which alter or inactivate the polypeptides of the present invention for use in therapy are also provided.

AN 2003:165489 USPATFULL

TI Identification and characterization of novel pneumococcal choline binding protein, CbpG, and diagnostic and therapeutic uses thereof

IN Tuomanen, Elaine I., Germantown, TN, UNITED STATES

Gosink, Khoosheh, Cordova, TN, UNITED STATES

Masure, Robert, Germantown, TN, UNITED STATES

PA St. Jude Children's Research Hospital (U.S. corporation)

PI US 2003113343 A1 20030619

AI US 2002-243977 A1 20020913 (10)

RLI Continuation of Ser. No. US 1999-287070, filed on 6 Apr 1999, GRANTED, Pat. No. US 6495139 Continuation-in-part of Ser. No. US 1998-196389, filed on 19 Nov 1998, ABANDONED

DT Utility

FS APPLICATION
LREP ALSTON AND BIRD LLP, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, BANK OF
AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC,
28280-4000
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 2801

L9 ANSWER 3 OF 64 USPTATFULL

AB The present invention relates to novel colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon or colon cancer antigens," and the use of such colon or colon cancer antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon or colon cancer associated nucleic acid molecules are provided encoding novel colon or colon cancer associated polypeptides. Novel colon or colon cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon or colon cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

AN 2003:160075 USPTATFULL

TI Colon and colon cancer associated polynucleotides and polypeptides

IN Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steve C., Rockville, MD, UNITED STATES

Birse, Charles E., North Potomac, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

PI US 2003109690 A1 20030612

AI US 2002-106698 A1 20020327 (10)

RLI Continuation-in-part of Ser. No. WO 2000-US26524, filed on 28 Sep 2000, PENDING

PRAI US 1999-157137P 19990929 (60)

US 1999-163280P 19991103 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 17981

L9 ANSWER 4 OF 64 USPTATFULL

AB The present invention provides novel polynucleotides encoding MMP-29 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MMP-29 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

AN 2003:159408 USPTATFULL

TI Polynucleotide encoding a novel metalloprotease highly expressed in the

testis, MMP-29
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
PI US 2003109021 A1 20030612
AI US 2002-133797 A1 20020426 (10)
PRAI US 2001-286764P 20010426 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 19916

L9 ANSWER 5 OF 64 USPATFULL

AB The present invention provides nucleic acids, proteins and vectors for a
method of nucleic acid, including DNA, immunization of a host, including
humans, against disease caused by infection by a strain of Chlamydia,
specifically C. pneumoniae. The method employs a vector containing a
nucleotide sequence encoding a myosin heavy chain of a strain of
Chlamydia pneumoniae and a promoter to effect expression of the myosin
heavy chain gene product in the host. Modifications are possible within
the scope of this invention.

AN 2003:146959 USPATFULL

TI Chlamydia antigens and corresponding DNA fragments and uses thereof

IN Murdin, Andrew D., Richmond Hill, CANADA

Oomen, Raymond P., Aurora, CANADA

Wang, Joe, Toronto, CANADA

Dunn, Pamela, Woodbridge, CANADA

PI US 2003100706 A1 20030529

AI US 2001-824584 A1 20010403 (9)

PRAI US 2000-194471P 20000404 (60)

DT Utility

FS APPLICATION

LREP BERNHARD D. SAXE, FOLEY & LARDNER, Washington Harbour, 3000 K Street,
N.W., Suite 500, Washington, DC, 20007-5109

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 1915

CAS. INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 64 USPATFULL

AB The present invention provides novel polynucleotides encoding HGPRBMY14
polypeptides, fragments and homologues thereof. Also provided are
vectors, host cells, antibodies, and recombinant and synthetic methods
for producing said polypeptides. The invention further relates to
diagnostic and therapeutic methods for applying these novel HGPRBMY14
polypeptides to the diagnosis, treatment, and/or prevention of various
diseases and/or disorders related to these polypeptides. The invention
further relates to screening methods for identifying agonists and
antagonists of the polynucleotides and polypeptides of the present
invention.

AN 2003:146311 USPATFULL

TI Novel human G-protein coupled receptor, HGPRBMY14, related to the orphan
GPCR, GPR73

IN Feder, John N., Belle Mead, NJ, UNITED STATES

Ramanathan, Chandra S., Wallingford, CT, UNITED STATES

Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

Kornacker, Michael, Princeton, NJ, UNITED STATES

Ryseck, Rolf-Peter, Ewing, NJ, UNITED STATES
Cacace, Angela, Clinton, CT, UNITED STATES
Barber, Lauren E., Jewett City, CT, UNITED STATES

PI US 2003100057 A1 20030529
AI US 2002-67649 A1 20020205 (10)
PRAI US 2001-266525P 20010205 (60)
US 2001-329897P 20011016 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 14451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 64 USPATFULL

AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

AN 2003:140506 USPATFULL

TI Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES

PI US 2003096347 A1 20030522
AI US 2002-120604 A1 20020411 (10)
PRAI US 2001-283145P 20010411 (60)
US 2001-283161P 20010411 (60)
US 2001-288468P 20010503 (60)
US 2001-300619P 20010625 (60)

DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 36 Drawing Page(s)
LN.CNT 20308

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 64 USPATFULL

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003096247 A1 20030522
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San
Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 64 USPATFULL
AB The isolation, characterization, cloning and expression of the lectin
(agglutinin) from Marasmius oreades (MOA) is described. MOA displays
unique carbohydrate binding properties, including blood group B-specific
agglutination and preferential binding to Gal.alpha.1,3Gal-containing
sugar epitopes, including but not limited to
Gal.alpha.1,3Gal.beta.1,4GlcNAc. MOA is contemplated as an affinity
reagent, a therapeutic in the treatment of antibiotic-induced diarrhea
and the field of xenotransplantation. MOA may also serve as a diagnostic
reagent, e.g. for malaria.
AN 2003:134024 USPATFULL
TI Isolation, characterization, cloning and use of a mushroom lectin
IN Goldstein, Irwin J., Ann Arbor, MI, UNITED STATES
Winter, Harry C., Ann Arbor, MI, UNITED STATES
Kruger, Robert P., Ann Arbor, MI, UNITED STATES
PA The Regents Of The University of Michigan, Ann Arbor, MI (U.S.
corporation)
PI US 2003092109 A1 20030515
AI US 2002-137077 A1 20020502 (10)
PRAI US 2001-288596P 20010503 (60)
US 2002-354322P 20020204 (60)
DT Utility
FS APPLICATION
LREP MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA,
94105
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 64 USPATFULL
AB The invention concerns GENSET polynucleotides and polypeptides. Such
GENSET products may be used as reagents in forensic analyses, as
chromosome markers, as tissue/cell/organelle-specific markers, in the
production of expression vectors. In addition, they may be used in
screening and diagnosis assays for abnormal GENSET expression and/or
biological activity and for screening compounds that may be used in the
treatment of GENSET-related disorders.
AN 2003:133926 USPATFULL
TI Human cDNAs and proteins and uses thereof

IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003092011 A1 20030515
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San
Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 64 USPATFULL
AB The present invention provides novel polynucleotides encoding HGPRBMY26
polypeptides, fragments and homologues thereof. Also provided are
vectors, host cells, antibodies, and recombinant and synthetic methods
for producing said polypeptides. The invention further relates to
diagnostic and therapeutic methods for applying these novel HGPRBMY26
polypeptides to the diagnosis, treatment, and/or prevention of various
diseases and/or disorders related to these polypeptides. The invention
further relates to screening methods for identifying agonists and
antagonists of the polynucleotides and polypeptides of the present
invention.
AN 2003:93022 USPATFULL
TI Polynucleotide encoding a novel human G-protein coupled receptor,
HGPRBMY26, expressed highly in testis and gastrointestinal tissues
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Cacace, Angela, Clinton, CT, UNITED STATES
Barber, Lauren E., Jewett City, CT, UNITED STATES
PI US 2003064381 A1 20030403
AI US 2002-92771 A1 20020307 (10)
PRAI US 2001-273963P 20010307 (60)
US 2001-278927P 20010327 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 12710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 64 USPATFULL
AB Disclosed and claimed are: epitopic regions of Pneumococcal Surface
Protein C or "PspC", different clades of PspC, isolated and/or purified
nucleic acid molecules such as DNA encoding a fragment or portion of
PspC such as an epitopic region of PspC or at least one epitope of PspC,
uses for such nucleic acid molecules, e.g., to detect the presence of
PspC or of *S. pneumoniae* by detecting a nucleic acid molecule therefor
in a sample such as by amplification and/or a polymerase chain reaction,
vectors or plasmids which contain and/or express such nucleic acid
molecules, e.g., in vitro or in vivo, immunological, immunogenic or

vaccine compositions including at least one PspC and/or a portion thereof (such as at least one epitopic region of at least one PspC and/or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in further combination with at least one second pneumococcal antigen, such as at least one different PspC and/or a fragment thereof and/or at least one PspA and/or at least one epitopic region of at least one PspA and/or at least one polypeptide including at least one epitope of PspA. PspC or a fragment thereof, and thus a composition including PspC or a fragment thereof, can be administered by the same routes, and in approximately the same amounts, as PspA. Thus, the invention further provides methods for administering PspC or a fragment thereof, as well as uses of PspC or a fragment thereof to formulate such compositions.

AN 2003:85835 USPATFULL
TI PNEUMOCOCCAL SURFACE PROTEIN C (PSPC), EPITOPIC REGIONS AND STRAIN
SELECTION THEREOF, AND USES THEREFOR
IN BRILES, DAVID E., BIRMINGHAM, AL, UNITED STATES
HOLLINGSHEAD, SUSAN K., BIRMINGHAM, AL, UNITED STATES
BROOKS-WALTER, ALEXIS, BIRMINGHAM, AL, UNITED STATES
PA NIXON PEABODY LLP (U.S. corporation)
PI US 2003059438 A1 20030327
AI US 1999-298523 A1 19990423 (9)
PRAI US 1998-82728P 19980423 (60)
DT Utility
FS APPLICATION
LREP Michael L Goldman, NIXON PEABODY LLP, Clinton Square, P O Box 31051,
Rochester, NY, 14603
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 50 Drawing Page(s)
LN.CNT 1957
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 64 USPATFULL
AB The present invention provides novel polynucleotides encoding K+betaM4 or K+betaM5 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+betaM4 or K+betaM5 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
AN 2003:79064 USPATFULL
TI Polynucleotide encoding two novel human potassium channel beta-subunits, K+betaM4 and K+betaM5
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
Carroll, Pamela, Princeton, NJ, UNITED STATES
PI US 2003054989 A1 20030320
AI US 2002-86156 A1 20020228 (10)
PRAI US 2001-272190P 20010228 (60)
US 2001-274258P 20010307 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20

ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 13779
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 64 USPATFULL

AB The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

AN 2003:78525 USPATFULL

TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01

IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES

PI US 2003054445 A1 20030320
AI US 2001-993180 A1 20011114 (9)
PRAI US 2000-248434P 20001114 (60)
US 2000-257610P 20001221 (60)
US 2001-282745P 20010410 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 52

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 14427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 64 USPATFULL

AB The present invention relates to novel colon related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon antigens," and the use of such colon antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon associated nucleic acid molecules are provided encoding novel colon associated polypeptides. Novel colon polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

AN 2003:71944 USPATFULL

TI Nucleic acids, proteins, and antibodies

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

PI	US 2003050231	A1	20030313
AI	US 2001-764872	A1	20010117 (9)
PRAI	US 2000-179065P		20000131 (60)
	US 2000-180628P		20000204 (60)
	US 2000-214886P		20000628 (60)
	US 2000-217487P		20000711 (60)
	US 2000-225758P		20000814 (60)
	US 2000-220963P		20000726 (60)
	US 2000-217496P		20000711 (60)
	US 2000-225447P		20000814 (60)
	US 2000-218290P		20000714 (60)
	US 2000-225757P		20000814 (60)
	US 2000-226868P		20000822 (60)
	US 2000-216647P		20000707 (60)
	US 2000-225267P		20000814 (60)
	US 2000-216880P		20000707 (60)
	US 2000-225270P		20000814 (60)
	US 2000-251869P		20001208 (60)
	US 2000-235834P		20000927 (60)
	US 2000-234274P		20000921 (60)
	US 2000-234223P		20000921 (60)
	US 2000-228924P		20000830 (60)
	US 2000-224518P		20000814 (60)
	US 2000-236369P		20000929 (60)
	US 2000-224519P		20000814 (60)
	US 2000-220964P		20000726 (60)
	US 2000-241809P		20001020 (60)
	US 2000-249299P		20001117 (60)
	US 2000-236327P		20000929 (60)
	US 2000-241785P		20001020 (60)
	US 2000-244617P		20001101 (60)
	US 2000-225268P		20000814 (60)
	US 2000-236368P		20000929 (60)
	US 2000-251856P		20001208 (60)
	US 2000-251868P		20001208 (60)
	US 2000-229344P		20000901 (60)
	US 2000-234997P		20000925 (60)
	US 2000-229343P		20000901 (60)
	US 2000-229345P		20000901 (60)
	US 2000-229287P		20000901 (60)
	US 2000-229513P		20000905 (60)
	US 2000-231413P		20000908 (60)
	US 2000-229509P		20000905 (60)
	US 2000-236367P		20000929 (60)
	US 2000-237039P		20001002 (60)
	US 2000-237038P		20001002 (60)
	US 2000-236370P		20000929 (60)
	US 2000-236802P		20001002 (60)
	US 2000-237037P		20001002 (60)
	US 2000-237040P		20001002 (60)
	US 2000-240960P		20001020 (60)
	US 2000-239935P		20001013 (60)
	US 2000-239937P		20001013 (60)
	US 2000-241787P		20001020 (60)
	US 2000-246474P		20001108 (60)
	US 2000-246532P		20001108 (60)
	US 2000-249216P		20001117 (60)
	US 2000-249210P		20001117 (60)
	US 2000-226681P		20000822 (60)
	US 2000-225759P		20000814 (60)
	US 2000-225213P		20000814 (60)
	US 2000-227182P		20000822 (60)
	US 2000-225214P		20000814 (60)

US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)

US 2000-226279P 20000818 (60)
 US 2000-186350P 20000302 (60)
 US 2000-184664P 20000224 (60)
 US 2000-189874P 20000316 (60)
 US 2000-198123P 20000418 (60)
 US 2000-227009P 20000823 (60)
 US 2000-235484P 20000926 (60)
 US 2000-190076P 20000317 (60)
 US 2000-209467P 20000607 (60)
 US 2000-205515P 20000519 (60)
 US 2001-259678P 20010105 (60)

DT Utility
 FS APPLICATION
 LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 22015

L9 ANSWER 16 OF 64 USPATFULL

AB The present invention provides novel polynucleotides encoding K+betaM6 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+betaM6 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

AN 2003:51158 USPATFULL

TI Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM6, expressed highly in the small intestine

IN Feder, John N., Belle Mead, NJ, UNITED STATES
 Lee, Liana, North Brunswick, NJ, UNITED STATES
 Chen, Jian, Princeton, NJ, UNITED STATES
 Jackson, Donald, Lawrenceville, NJ, UNITED STATES
 Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
 Siemers, Nathan O., Pennington, NJ, UNITED STATES
 Chang, Han, Princeton Junction, NJ, UNITED STATES

PI US 2003036115 A1 20030220
 AI US 2002-80980 A1 20020221 (10)
 PRAI US 2001-270132P 20010221 (60)
 US 2001-278953P 20010327 (60)

DT Utility
 FS APPLICATION
 LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN 8 Drawing Page(s)
 LN.CNT 12296
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 64 USPATFULL

AB The present invention provides novel polynucleotides encoding HGRA4 polypeptides, fragments and homologues thereof. The present invention also provides novel polynucleotides encoding a HGRA4 splice variant, HGRA4sv. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGRA4 and HGRA4sv polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to

screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

AN 2003:45296 USPATFULL

TI Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, HGRA4, and splice variant thereof

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES

PI US 2003032608 A1 20030213

AI US 2002-75846 A1 20020213 (10)

PRAI US 2001-269535P 20010216 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 13 Drawing Page(s)

LN.CNT 12638

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 64 USPATFULL

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

AN 2003:37603 USPATFULL

TI Human cDNAs and proteins and uses thereof

IN Bejanin, Stephane, Paris, FRANCE

Tanaka, Hiroaki, Antony, FRANCE

PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

PI US 2003027248 A1 20030206

AI US 2001-924340 A1 20010806 (9)

PRAI US 2001-305456P 20010713 (60)

US 2001-302277P 20010629 (60)

US 2001-298698P 20010615 (60)

US 2001-293574P 20010525 (60)

DT Utility

FS APPLICATION

LREP GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY RD, SAN DIEGO, CA, 92121

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 25650

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 64 USPATFULL

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

AN 2003:37516 USPATFULL

TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027161 A1 20030206
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San
Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 64 USPATFULL
AB A method is provided for the purification of **Clostridium**
difficile Toxin A antigen comprising
reacting impure **Toxin A** with immobilized
mono-specific polyclonal antibodies. The polyclonal antibodies are
coupled to a hydrazide group containing matrix such as hydrazide
activated agarose gel. The immobilized antibody is specific for
Toxin A and will greatly purify **Toxin**
A from a **Toxin A** containing solution.
Antibodies raised to **Toxin A** purified according to
the method are of higher activity than antibodies produced from prior
art purified **Toxin A**.
AN 2003:24326 USPATFULL
TI Mono-specific polyclonal antibodies and methods for detecting
Clostridium difficile Toxin A
IN Deutsch, John William, Marietta, GA, UNITED STATES
PI US 2003018170 A1 20030123
AI US 2002-224752 A1 20020820 (10)
RLI Continuation-in-part of Ser. No. US 1997-797959, filed on 10 Feb 1997,
PENDING
DT Utility
FS APPLICATION
LREP THOMAS, KAYDEN, HORSTEMEYER & RISLEY, LLP, 100 GALLERIA PARKWAY, NW, STE
1750, ATLANTA, GA, 30339-5948
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 64 USPATFULL
AB The invention provides isolated polypeptide and nucleic acid sequences
derived *Enterococcus faecium* that are useful in diagnosis and therapy of
pathological conditions; antibodies against the polypeptides; and
methods for the production of the polypeptides. The invention also
provides methods for the detection, prevention and treatment of
pathological conditions resulting from bacterial infection.
AN 2003:169096 USPATFULL
TI Nucleic acid sequences and expression system relating to *Enterococcus*
faecium for diagnostics and therapeutics
IN Doucette-Stamm, Lynn A., Framingham, MA, United States
Bush, David, Somerville, MA, United States

PA Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)
PI US 6583275 B1 20030624
AI US 1998-107532 19980630 (9)
PRAI US 1998-85598P 19980514 (60)
US 1997-51571P 19970702 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Marschel, Ardin H.
LREP Genome Therapeutics Corporation
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 15265

L9 ANSWER 22 OF 64 USPATFULL

AB Compositions and methods are described for preventing and treating sepsis in humans and other animals. Surgical patients, low birth weight infants, burn and trauma victims, as well as other individuals at risk can be treated prophylactically. Methods for treating acute infections with advantages over current therapeutic approaches are provided.

AN 2003:161878 USPATFULL

TI Polymyxin B **conjugates**

IN Shekhani, Mohammed Saleh, Madison, WI, United States

Schatz, Robert W., New Glarus, WI, United States

Pugh, Charles, Middleton, WI, United States

Panasik, Jr., Nicholas, Madison, WI, United States

Stafford, Douglas, Madison, WI, United States

PA Promega Corporation, Madison, WI, United States (U.S. corporation)

PI US 6579696 B1 20030617

AI US 1995-482191 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1993-169701, filed on 17 Dec 1993, now patented, Pat. No. US 5545721 Continuation-in-part of Ser. No. US 1992-995388, filed on 21 Dec 1992, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Navarro, Mark

LREP Medlen & Carroll, LLP

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 19 Drawing Figure(s); 19 Drawing Page(s)

LN.CNT 6203

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 23 OF 64 USPATFULL

AB The present invention is directed to chemical **conjugates** (herein referred to as **polysaccharide** adjuvant-antigen **conjugates**) that have a **polysaccharide** backbone capable of binding to the cell surface of Antigen Presenting Cells (APCs), to which is covalently attached (a) one or more molecules having a stable carbonyl group (i.e. an aldehyde and ketone group that is capable of reacting with amino groups to form an imine or Schiff base), and (b) one or more polypeptides or peptides that are capable of eliciting an immunogenic response when covalently attached to **polysaccharide** backbone. Also disclosed are methods for making the **conjugates** and methods of using the **conjugates** to enhance the potentiation of an immune response in a mammal. Also disclosed is a method of vaccination, and pharmaceutical and veterinary compositions comprising one or more of the **polysaccharide** adjuvant-antigen **conjugates** of the present invention.

AN 2003:148972 USPATFULL

TI Modified **polysaccharide** adjuvant-protein antigen **conjugates**, the preparation thereof and the use thereof

IN Marciiani, Dante J., Birmingham, AL, United States

PA Galenica Pharmaceuticals, Inc., Birmingham, AL, United States (U.S. corporation)
PI US 6573245 B1 20030603
AI US 1999-301115 19990428 (9)
PRAI US 1998-83106P 19980428 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Barts, Samuel; Assistant Examiner: Khare, Devesh
LREP Sterne, Kessler, Goldstein & Fox, P.L.L.C.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1879
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 24 OF 64 USPATFULL

AB An invention is provided whereby methods and compositions having angiostatic activity are utilized to treat angioproliferative disorders, to prevent conception, and to treat a wide variety of pathologies in which it is desirable to limit the production of new vasculature. Specifically, compositions containing proteinases derived from the pathogen *Porphyromonas gingivalis* capable of treating cancer through disruption of cell-cell and cell-matrix adhesion bonds associated with malignant tumor proliferation are disclosed.

AN 2002:336852 USPATFULL

TI Methods and compositions for angioproliferative disorder treatment

IN Kozarov, Emil V., Gainesville, FL, UNITED STATES
Progulske-Fox, Ann, Gainesville, FL, UNITED STATES

PI US 2002192206 A1 20021219
AI US 2001-849115 A1 20010505 (9)

DT Utility

FS APPLICATION

LREP MCDONNELL BOEHNNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 24 Drawing Page(s)

LN.CNT 1015

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 25 OF 64 USPATFULL

AB The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host. The methods employ **conjugates** comprising superantigen polypeptides, nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid **conjugates** and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compositions are tumor cells, hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are tumoricidal T cells and NKT cells devoid of inhibitory receptors or inhibitory signaling motifs which are hyperresponsive to the the above compositions and lipid-based tumor associated antigens that can be administered for adoptive immunotherapy of cancer and infectious diseases.

AN 2002:315069 USPATFULL

TI Compositions and methods for treatment of neoplastic disease

IN Terman, David S., Pebble Beach, CA, UNITED STATES

PI US 2002177551 A1 20021128
AI US 2001-870759 A1 20010530 (9)

PRAI US 2000-208128P 20000531 (60)

DT Utility
FS APPLICATION
LREP David S. Terman, P.O. Box 987, Pebble Beach, CA, 93953
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 17323
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 26 OF 64 USPATFULL

AB The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a nucleotide sequence encoding a myosin heavy chain homolog of a strain of Chlamydia pneumoniae and a promoter to effect expression of the myosin heavy chain homolog gene product in the host. Modifications are possible within the scope of this invention.

AN 2002:243800 USPATFULL

TI Chlamydia antigens and corresponding DNA fragments and uses thereof

IN Murdin, Andrew D., Richmond Hill, CANADA

Oomen, Raymond P., Aurora, CANADA

Wang, Joe; Toronto, CANADA

Dunn, Pamela, Woodbridge, CANADA

PI US 2002132994 A1 20020919

AI US 2001-824568 A1 20010403 (9)

PRAI US 2000-194475P 20000404 (60)

DT Utility

FS APPLICATION

LREP BERNHARD D. SAXE, FOLEY & LARDNER, Suite 500, 3000 K Street N.W.,
Washington, DC, 20007-5109

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 1955

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 27 OF 64 USPATFULL

AB The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a nucleotide sequence encoding a glutamate binding protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the glutamate binding protein gene product in the host. Modifications are possible within the scope of this invention.

AN 2002:179175 USPATFULL

TI Chlamydia antigens and corresponding DNA fragments and uses thereof

IN Murdin, Andrew D., Richmond Hill, CANADA

Oomen, Raymond P., Aurora, CANADA

Wang, Joe, Toronto, CANADA

Dunn, Pamela, Woodbridge, CANADA

PI US 2002094965 A1 20020718

AI US 2001-824206 A1 20010403 (9)

PRAI US 2000-194472P 20000404 (60)

DT Utility

FS APPLICATION

LREP BERNHARD D. SAXE, FOLEY & LARDNER, Suite 500, 3000 K Street, N.W.,
Washington, DC, 20007-5109

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 1951

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 28 OF 64 USPATFULL

AB The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a nucleotide sequence encoding a transmembrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the transmembrane protein gene product in the host. Modifications are possible within the scope of this invention.

AN 2002:157792 USPATFULL

TI Chlamydia antigens and corresponding DNA fragments and uses thereof

IN Murdin, Andrew D., Richmond Hill, CANADA

Oomen, Raymond P., Aurora, CANADA

Wang, Joe, Toronto, CANADA

Dunn, Pamela, Woodbridge, CANADA

PI US 2002082402 A1 20020627

AI US 2001-824588 A1 20010403 (9)

PRAI US 2000-194477P 20000404 (60)

DT Utility

FS APPLICATION

LREP BERNHARD D. SAXE, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)

LN.CNT 2047

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 29 OF 64 USPATFULL

AB The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a nucleotide sequence encoding an ATP-binding cassette of a strain of Chlamydia pneumoniae and a promoter to effect expression of the ATP-binding cassette gene product in the host. Modifications are possible within the scope of this invention.

AN 2002:140850 USPATFULL

TI Chlamydia antigens and corresponding DNA fragments and uses thereof

IN Murdin, Andrew D., Richmond Hill, CANADA

Oomen, Raymond P., Aurora, CANADA

Wang, Joe, Toronto, CANADA

Dunn, Pamela, Woodbridge, CANADA

PI US 2002071831 A1 20020613

AI US 2001-824567 A1 20010403 (9)

PRAI US 2000-194464P 20000404 (60)

DT Utility

FS APPLICATION

LREP Bernhard D. Saxe, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN 11 Drawing Page(s)

LN.CNT 1835

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 30 OF 64 USPATFULL

AB The present invention provides isolated polypeptides comprising an amino acid sequence of a choline binding protein CbpG. This invention provides an isolated polypeptide comprising an amino acid sequence of a choline binding polypeptide CbpG or N-terminal CbpG truncate, including analogs, variants, mutants, derivatives and fragments thereof. This invention further provides an isolated immunogenic polypeptide comprising an amino

acid sequence of a choline binding protein CbpG. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a choline binding protein CbpG. This invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids. Assays for compounds which alter or inactivate the polypeptides of the present invention for use in therapy are also provided.

AN 2002:78228 USPATFULL
TI IDENTIFICATION AND CHARACTERIZATION OF NOVEL PNEUMOCOCCAL CHOLINE
BINDING PROTEIN, CBPG, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
IN TUOMANEN, ELAINE I., GERMANTOWN, TN, UNITED STATES
GOSINK, KHOOSHEH, CORDOVA, TN, UNITED STATES
MASURE, ROBERT, GERMANTOWN, TN, UNITED STATES
PI US 2002041881 A1 20020411
US 6495139 B2 20021217
AI US 1999-287070 A1 19990406 (9)
RLI Continuation-in-part of Ser. No. US 1998-196389, filed on 19 Nov 1998,
ABANDONED
DT Utility
FS APPLICATION
LREP DAVID A JACKSON ESQ, KLAUBER & JACKSON, 411 HACKENSACK AVENUE,
HACKENSACK, NJ, 07601
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 2806
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 31 OF 64 USPATFULL

AB The present invention relates to pneumococcal genes, portions thereof,
expression products therefrom and uses of such genes, portions and
products; especially to genes of Streptococcus pneumoniae, e.g., the
gene encoding pneumococcal surface protein A (PspA), i.e., the pspA
gene, the gene encoding pneumococcal surface protein A-like proteins,
such as pspA-like genes, e.g., the gene encoding pneumococcal surface
protein C (PspC); i.e., the pspC gene, portions of such genes,
expression products therefrom, and the uses of such genes, portions
thereof and expression products therefrom.
AN 2002:346772 USPATFULL
TI Pneumococcal surface proteins and uses thereof
IN Briles, David E., Birmingham, AL, United States
McDaniel, Larry S., Ridgland, MS, United States
Swiatlo, Edwin, Birmingham, AL, United States
Yother, Janet, Birmingham, AL, United States
Crain, Marilyn J., Birmingham, AL, United States
Hollingshead, Susan, Birmingham, AL, United States
Tart, Rebecca, Benson, NC, United States
Brooks-Walter, Alexis, Birmingham, AL, United States
PA University of Alabama at Birmingham, Birmingham, AL, United States (U.S.
corporation)
PI US 6500613 B1 20021231
AI US 1996-714741 19960916 (8)
RLI Continuation-in-part of Ser. No. US 1995-529055, filed on 15 Sep 1995
DT Utility
FS GRANTED
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Swartz, Rodney
P.
LREP Frommer Lawrence & Haug LLP, Frommer, William S., Kowalski, Thomas J.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 71 Drawing Figure(s); 69 Drawing Page(s)
LN.CNT 7865
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 32 OF 64 USPATFULL

AB This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including **Clostridium difficile** associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with C. difficile infection, using oligosaccharide compositions which bind C. difficile toxin B. More specifically, the invention concerns neutralization of C. difficile toxin B associated with such conditions.

AN 2002:268740 USPATFULL

TI Treatment of C. difficile toxin B associated conditions

IN Heerze, Louis D., Edmonton, CANADA

Armstrong, Glen D., Edmonton, CANADA

PA SYNSORB Biotech, Inc., Calgary, CANADA (non-U.S. corporation)

PI US 6465435 B1 20021015

AI US 2000-593040 20000613 (9)

RLI Continuation of Ser. No. US 1999-419790, filed on 18 Oct 1999, now patented, Pat. No. US 6107282 Continuation of Ser. No. US 1998-85032, filed on 28 May 1998, now patented, Pat. No. US 6013635

DT Utility

FS GRANTED

EXNAM Primary Examiner: Horlick, Kenneth R.; Assistant Examiner: Spiegler, Alexander H.

LREP Burns, Doane, Swecker & Mathis LLP

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 989

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 33 OF 64 USPATFULL

AB This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including **Clostridium difficile** associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with C. difficile infection, using oligosaccharide compositions which bind C. difficile toxin B. More specifically, the invention concerns neutralization of C. difficile toxin B associated with such conditions.

AN 2002:57766 USPATFULL

TI Treatment of C. difficile toxin B associated conditions

IN Heerze, Louis D., Edmonton, CANADA

Armstrong, Glen D., Edmonton, CANADA

PA Synsorb Biotech Inc., CANADA (non-U.S. corporation)

PI US 6358930 B1 20020319

AI US 1999-433944 19991104 (9)

RLI Continuation-in-part of Ser. No. US 1998-85032, filed on 28 May 1998, now patented, Pat. No. US 6013635

DT Utility

FS GRANTED

EXNAM Primary Examiner: Fonda, Kathleen K.

LREP Burns Doane Swecker & Mathis LLP

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 5 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1216

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 34 OF 64 USPATFULL

AB Disclosed and claimed are: epitopic regions of Pneumococcal Surface Protein C or "PspC", different clades of PspC, isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such nucleic acid molecules, e.g., to detect the presence of PspC or of S. pneumoniae by detecting a nucleic acid molecule therefor in a sample such as by amplification and/or a polymerase chain reaction,

vectors or plasmids which contain and/or express such nucleic acid molecules, e.g., in vitro or in vivo, immunological, immunogenic or vaccine compositions including at least one PspC and/or a portion thereof (such as at least one epitopic region of at least one PspC and/or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in further combination with at least one second pneumococcal antigen, such as at least one different PspC and/or a fragment thereof and/or at least one PspA and/or at least one epitopic region of at least one PspA and/or at least one polypeptide including at least one epitope of PspA. PspC or a fragment thereof, and thus a composition including PspC or a fragment thereof, can be administered by the same routes, and in approximately the same amounts, as PspA. Thus, the invention further provides methods for administering PspC or a fragment thereof, as well as uses of PspC or a fragment thereof to formulate such compositions.

AN 2001:139158 USPATFULL
TI Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
IN Briles, David E., Birmingham, AL, United States
Hollingshead, Susan K., Birmingham, AL, United States
Brooks-Walter, Alexis, Birmingham, AL, United States
PI US 2001016200 A1 20010823
AI US 2000-748875 A1 20001226 (9)
RLI Division of Ser. No. US 1999-298523, filed on 23 Apr 1999, PENDING
PRAI US 1998-82728P 19980423 (60)
DT Utility
FS APPLICATION
LREP FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE, NEW YORK, NY, 10151
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 50 Drawing Page(s)
LN.CNT 1911
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 35 OF .64 USPATFULL

AB A method of inhibiting the growth of a bacterial species in a human or non-human vertebrate employs the antimicrobial (i.e., antibiotic) properties of 5-aminosalicylates. These antimicrobial properties are also employed in an antimicrobial method of inhibiting the growth of a bacterial species in a foodstuff and in foodstuffs containing a 5-aminosalicylate compound. Pharmaceutical compositions, foodstuffs, food containers, food-handling implements, cleansers, polishes, paints, sprays, soaps, or detergents comprise 5-aminosalicylate compounds, such as mesalamine, sulphasalazine, olsalazine, ipsalazine, salicylazobenzoic acid, balsalazide, or **conjugated** bile acids, including ursodeoxycholic acid-5-aminosalicylic acid. The present pharmaceutical compositions can be formulated for ingestive, colonic, or topical non-systemic delivery systems or for any systemic delivery systems. Formulation can be for human or veterinary administration. Using the method and pharmaceutical preparations the growth of bacterial species, such as *Clostridium perfringens*, *Clostridium difficile*, *Clostridium botulinum*, and *Clostridium tetani* can be inhibited.

AN 2001:221042 USPATFULL
TI Use of 5-aminosalicylates as antimicrobial agents
IN Lin, Henry C., Manhattan Beach, CA, United States
Pimentel, Mark, Los Angeles, CA, United States
PA Cedars-Sinai Medical Center, Los Angeles, CA, United States (U.S. corporation)
PI US 6326364 B1 20011204
AI US 1999-246645 19990208 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Sidley Austin Brown & Wood

CLMN Number of Claims: 84
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 36 OF 64 USPATFULL

AB Compounds which bind to toxins associated with enteric bacterial infection, compositions including the compounds, methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are disclosed. Toxins which can be bound by the compounds include pentameric toxins, for example SLTs, such as those from salmonella, camylobacter and other bacteria, verotoxins from E. coli, cholera toxin, **clostridium difficile** toxins A and B, bacterial pili from enteropathogenic E. coli (EPEC) and enterotoxigenic E. coli (ETEC) and viral lectins such as viral hemagglutinins. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to at least one, and preferably, two or more ligands which bind to the toxin. The presence of a plurality of bridged dimers of the ligands is responsible for the increased binding affinity of the compounds relative to the ligands themselves. In one embodiment, the compounds, when administered in a timely fashion to a patient suffering from enteric E. coli infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).

AN 2001:191114 USPATFULL

TI Treatment of bacterial infections

IN Bundle, David R., Edmonton, Canada

Kitov, Pavel, Edmonton, Canada

Read, Randy J., Cambridge, United Kingdom

Ling, Hong, Edmonton, Canada

Armstrong, Glen, Edmonton, Canada

PA Governors of the University of Alberta, Edmonton, Canada (non-U.S. corporation)

PI US 6310043 B1 20011030

AI US 1999-317290 19990524 (9)

RLI Continuation-in-part of Ser. No. US 1998-130495, filed on 7 Aug 1998, now patented, Pat. No. US 5962423

DT Utility

FS GRANTED

EXNAM Primary Examiner: Fonda, Kathleen K.

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 26 Drawing Page(s)

LN.CNT 2339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 37 OF 64 USPATFULL

AB The present invention is directed to novel bidesmosidic saponin derivatives comprising a triterpene aglycone core substituted at positions 3 and 28 with a monosaccharide or an oligosaccharide which can be the same or different, and having an aldehyde group attached to the core, preferably at the 4-position. The novel derivatives include a lipophilic group that is covalently attached to the 4-position of a fucosyl group that is required in the 28-oligosaccharide substituent. These derivatives preferably have Formula I: ##STR1##

wherein Z and R.sup.1 to R.sup.3 are defined herein. The present invention is also directed to pharmaceutical and veterinary compositions comprising one or more compounds of the present invention. These compositions may be employed as immunopotentiators in animals and humans. The present invention is also directed to methods of making

these compounds and to methods of using these compounds as immunostimulating agents and as adjuvants.

AN 2001:112295 USPATFULL
TI Chemically modified saponins and the use thereof as adjuvants
IN Press, Jeffery B., Brewster, NY, United States
Marciani, Dante J., Birmingham, AL, United States
PA Galenica Pharmaceuticals, Inc., Frederick, MD, United States (U.S. corporation)
PI US 6262029 B1 20010717
AI US 1999-373660 19990813 (9)
PRAI US 1998-96691P 19980814 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Lee, Howard C.
LREP Sterne, Kessler, Goldstein & Fox, P.L.L.C.
CLMN Number of Claims: 38
ECL Exemplary Claim: 3
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2502
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 38 OF 64 USPATFULL

AB The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.

AN 2001:86039 USPATFULL
TI Choline binding proteins for anti-pneumococcal vaccines
IN Masure, H. Robert, Germantown, TN, United States
Rosenow, Carsten I., New York, NY, United States
Tuomanen, Elaine, Germantown, TN, United States
Wizemann, Theresa M., Germantown, MD, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 6245335 B1 20010612
AI US 1997-847065 19970501 (8)
PRAI US 1996-16632P 19960501 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Mosher, Mary E.
LREP Klauber & Jackson
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 2933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 39 OF 64 USPATFULL

AB Disclosed are novel 1-galactose derivatives having a carbon- or nitrogen-containing aglycon linkage. The disclosed compounds inhibit binding of toxins, such as heat-labile enterotoxin or cholera toxin, to their receptors either in vitro or in vivo. The disclosed compounds also inhibit binding of enterovirulent organisms (e.g., bacteria, virus, fungi, and the like), such as *Vibrio cholerae* and enterotoxigenic

strains of Escherichia coli, to their cell surface receptors.

AN 2001:8034 USPATFULL

TI 1-galactose derivatives having a carbon- or nitrogen-containing aglycon linkage

IN Hindsgaul, Ole, Edmonton, Canada

PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)

PI US 6174867 B1 20010116

AI US 1998-75427 19980508 (9)

DT Utility

FS Granted

EXNAM Primary Examiner: Lee, Howard C.

LREP Burns, Doane, Swecker & Mathis LLP

CLMN Number of Claims: 64

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 1979

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 40 OF 64 CAPLUS COPYRIGHT 2003 ACS

AB The present invention provides for immunogenic compns. and their methods of use as vaccines and their method of prepn. These immunogenic compns. comprise a recombinant protein of **toxin A** of **Clostridium difficile** conjugated to a **polysaccharide** of a microbial pathogen. The immunogenic compns. may include only a nontoxic truncated portion of **toxin A**, particularly the repeating units (rARU), that is **conjugated** to a microbial pathogen **polysaccharide**. The yields of these **polysaccharide-protein conjugates** can be significantly increased by prior treatment of rARU with succinic anhydride. Such compns. are effective in eliciting T-cell dependent and antibody responses, and immune responses to pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a **polysaccharides** in mice are demonstrated. All **conjugates** elicited high levels of serum IgG both to the **polysaccharides** and to CDTA. These compns. are therefore effective as vaccines for humans, particularly children, and animals in affording protection against one or more microbial pathogens.

AN 2000:742256 CAPLUS

DN 133:295361

TI **Clostridium difficile** recombinant **toxin A** repeating units as a carrier protein for **conjugate** vaccines

IN Wilkins, Tracy D.; Lylerly, David M.; Moncrief, J. Scott; Pavliakova, Danka; Scheerson, Rachel; Robbins, John B.

PA Techlab, Inc., USA; United States Dept. of Health and Human Services

SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061761	A2	20001019	WO 2000-US9523	20000410
	WO 2000061761	A3	20010222		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1165796	A2	20020102	EP 2000-923206	20000410
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO
JP 2002541808 T2 20021210 JP 2000-611684 20000410
PRAI US 1999-128686P P 19990409
US 2000-186201P P 20000301
WO 2000-US9523 W 20000410

L9 ANSWER 41 OF 64 USPATFULL

AB This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including *Clostridium difficile* associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with *C. difficile* infection, using oligosaccharide compositions which bind *C. difficile* toxin B. More specifically, the invention concerns neutralization of *C. difficile* toxin B associated with such conditions.

AN 2000:109787 USPATFULL

TI Treatment of *C. difficile* toxin B associated conditions

IN Heerze, Louis D., Edmonton, Canada

Armstrong, Glen D., Edmonton, Canada

PA SYNORB Biotech, Inc., Calgary, Canada (non-U.S. corporation)

PI US 6107282 20000822

AI US 1999-419790 19991018 (9)

RLI Continuation of Ser. No. US 1998-85032, filed on 28 May 1998, now patented, Pat. No. US 6013635

DT Utility

FS Granted

EXNAM Primary Examiner: Fonda, Kathleen K.

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 1256

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 42 OF 64 USPATFULL

AB Disclosed are novel saccharide derivatives which inhibit binding of toxins, such as heat-labile enterotoxin or cholera toxin, to their receptors either in vitro or in vivo. Additionally, disclosed are compounds which inhibit binding of enterovirulent organisms (e.g., bacteria, virus, fungi, and the like), such as *Vibrio cholerae* and enterotoxigenic strains of *Escherichia coli*, to their cell surface receptors.

AN 2000:88168 USPATFULL

TI Saccharide derivatives

IN Hindsgaul, Ole, Edmonton, Canada

PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)

PI US 6087339 20000711

AI US 1997-970751 19971114 (8)

RLI Continuation-in-part of Ser. No. US 1996-751510, filed on 15 Nov 1996

PRAI US 1996-30794P 19961114 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Pesellev, Elli

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 71

ECL Exemplary Claim: 19,20,21,34

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 3550

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 43 OF 64 USPATFULL

AB The present invention is directed to vaccines comprising (1) one or more bacterial, viral or tumor-associated antigens; and (2) one or more saponin-lipophile conjugate in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently

attached to a non-acylated or desacylated triterpene saponin via a carboxyl group present on the 3-O-glucuronic acid of the triterpene saponin. The attachment of a lipophile moiety to the 3-O-glucuronic acid of a saponin such as Quillaja desacylsaponin, lucyoside P, or saponin from Gypsophila, Saponaria and Acanthophyllum enhances their adjuvant effects on humoral and cell mediated immunity. Additionally, the attachment of a lipophile moiety to the 3-O-glucuronic acid residue of non- or des-acylsaponin yields a saponin analog that is easier to purify, less toxic, chemically more stable, and possesses equal or better adjuvant properties than the original saponin.

AN 2000:80733 USPTFULL
TI Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
IN Marcianni, Dante J., Birmingham, AL, United States
PA Galenica Pharmaceuticals, Inc., Frederick, MD, United States (U.S. corporation)
PI US 6080725 20000627
AI US 1999-290606 19990413 (9)
RLI Continuation-in-part of Ser. No. US 1998-81647, filed on 20 May 1998, now patented, Pat. No. US 5977081
PRAI US 1997-47129P 19970520 (60)
US 1998-80389P 19980402 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Howard C.
LREP Sterne, Kessler, Goldstein & Fox, P.L.L.C.
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 44 OF 64 USPTFULL

AB This invention relates to treatment of traveller's diarrhea, including diarrhea caused by enterotoxigenic E. coli (ETEC), using oligosaccharide compositions which bind E. coli heat-labile toxin (LT) and/or one or more serotypes of enterotoxigenic E. coli organisms. More specifically, the invention concerns neutralization and removal of LT associated with traveller's diarrhea. This invention also relates to prevention of ETEC from colonizing the intestinal tract and inducing disease.

AN 2000:67726 USPTFULL
TI Treatment of traveller's diarrhea
IN Heerze, Louis D., Edmonton, Canada
Armstrong, Glen D., Edmonton, Canada
PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)
PI US 6069137 20000530
WO 9639190 19961212
AI US 1998-973951 19980430 (8)
WO 1996-CA145 19960311
19980430 PCT 371 date
19980430 PCT 102(e) date

DT Utility
FS Granted
EXNAM Primary Examiner: Wilson, James O.
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1112
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 45 OF 64 USPTFULL

AB This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including *Clostridium difficile*

associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with *C. difficile* infection, using oligosaccharide compositions which bind *C. difficile* toxin B. More specifically, the invention concerns neutralization of *C. difficile* toxin B associated with such conditions.

AN 2000:4797 USPTAFULL
TI Treatment of *C. difficile* toxin B associated conditions
IN Heerze, Louis D., Edmonton, Canada
Armstrong, Glen D., Edmonton, Canada
PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)
PI US 6013635 20000111
AI US 1998-85032 19980528 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Fonda, Kathleen K.
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1139
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 46 OF 64 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE

AB Unlike the native protein, a nontoxic peptide (repeating unit of the native toxin designated rARU) from *Clostridium difficile* toxin A (CDTA) afforded an antigen that could be bound covalently to the surface polysaccharides of pneumococcus type 14, *Shigella flexneri* type 2a, and *Escherichia coli* K1. The yields of these polysaccharide-protein conjugates were significantly increased by prior treatment of rARU with succinic anhydride. Conjugates, prepared with rARU or succinylated (rARUsucc), were administered to mice by a clinically relevant dosage and immunization scheme. All conjugates elicited high levels of serum immunoglobulin G both to the polysaccharides and to CDTA. Conjugate-induced anti-CDTA had neutralizing activity in vitro and protected mice challenged with CDTA, similar to the rARU alone. Conjugates prepared with succinylated rARU, therefore, have potential for serving both as effective carrier proteins for polysaccharides and for preventing enteric disease caused by *C. difficile*.

AN 2000:186662 BIOSIS
DN PREV200000186662
TI *Clostridium difficile* recombinant toxin
A repeating units as a carrier protein for conjugate vaccines: Studies of pneumococcal type 14, *Escherichia coli* K1, and *Shigella flexneri* type 2a polysaccharides in mice.
AU Pavliakova, Danko; Moncrief, J. Scott; Lyster, David M.; Schiffman, Gerald; Bryla, Dolores A.; Robbins, John B.; Schneerson, Rachel (1)
CS (1) National Institutes of Health, Building 6, Room 424, Bethesda, MD, 20892 USA
SO Infection and Immunity, (April, 2000) Vol. 68, No. 4, pp. 2161-2166.
ISSN: 0019-9567.
DT Article
LA English
SL English

L9 ANSWER 47 OF 64 USPTAFULL

AB Diagnostics and treatments for bacterial infection are disclosed. The treatments prevent bacteria from adhering to host cells by interfering with the binding of the bacteria to cell receptors. Compounds that inhibit bacterial adherence to cells are engineered to be readily modified for best efficacy with different modes of treatment. The compounds can be readily modified for use to identify bacteria according

to their cell binding specificities.

AN 1999:159997 USPATFULL

TI Compounds that bind bacterial pili

IN Shekhani, Mohammed Saleh, Madison, WI, United States
 Firca, Joseph R., Vernon Hills, IL, United States
 Anderson, Byron, Morton Grove, IL, United States

PA Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

PI US 5998381 19991207

AI US 1996-760903 19961206 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Peselev, Elli

LREP Medlen & Carroll, LLP

CLMN Number of Claims: 24

ECL Exemplary Claim: 5

DRWN 23 Drawing Figure(s); 25 Drawing Page(s)

LN.CNT 6570

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 48 OF 64 USPATFULL

AB Disclosed are novel 1-thiogalactose derivatives which inhibit binding of toxins, such as heat-labile enterotoxin or cholera toxin, to their receptors either in vitro or in vivo. Additionally, disclosed are compounds which inhibit binding of organisms (e.g., bacteria, virus, fungi, and the like), such as Vibrio cholerae and enterotoxigenic strains of Escherichia coli, to their cell surface receptors.

AN 1999:128523 USPATFULL

TI 1-thiogalactose derivatives

IN Hindsgaul, Ole, Edmonton, Canada

PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)

PI US 5968907 19991019

AI US 1997-970384 19971114 (8)

RLI Continuation-in-part of Ser. No. US 1996-751510, filed on 15 Nov 1996, now patented, Pat. No. US 5780603

PRAI US 1996-30794P 19961114 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Peselev, Elli

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 87

ECL Exemplary Claim: 66,80

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 4579

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 49 OF 64 USPATFULL

AB This invention relates to treatment of cholera and related conditions using oligosaccharide compositions which bind V. cholera toxin and/or one or more serotypes of the organism V. cholera. More specifically, the invention concerns neutralization and removal of V. cholera toxin and/or organisms from the intestinal tract.

AN 1999:96348 USPATFULL

TI Treatment of cholera

IN Heerze, Louis D., Edmonton, Canada
 Armstrong, Glen D., Edmonton, Canada

PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)

PI US 5939397 19990817
 WO 9639191 19961212

AI US 1998-973630 19980325 (8)
 WO 1996-CA251 19960418
 19980325 PCT 371 date
 19980325 PCT 102(e) date

DT Utility

FS Granted
EXNAM Primary Examiner: Jordan, Kimberly
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 50 OF 64 USPATFULL
AB Disclosed are novel 1-galactose derivatives which inhibit binding of toxins, such as heat-labile enterotoxin or cholera toxin, to their receptors either in vitro or in vivo. Additionally, disclosed are compounds which inhibit binding of enterovirulent organisms (e.g., bacteria, virus, fungi, and the like), such as Vibrio cholerae and enterotoxigenic strains of Escherichia coli, to their cell surface receptors.
AN 1999:89130 USPATFULL
TI 1-galactose derivatives
IN Hindsgaul, Ole, Edmonton, Canada
PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)
PI US 5932554 19990803
AI US 1997-970749 19971114 (8)
RLI Continuation-in-part of Ser. No. US 1996-751510, filed on 15 Nov 1996
PRAI US 1996-30794P 19961114 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Pesellev, Elli
LREP Burns Doane Swecker & Mathis
CLMN Number of Claims: 62
ECL Exemplary Claim: 14,27
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2244
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 51 OF 64 USPATFULL
AB A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides **polysaccharide** -protein moieties and contain (a) a group B Streptococcus **polysaccharide conjugated** to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such **polysaccharide-protein** unit or may contain a mixture of more than one type of unit.
AN 1999:63102 USPATFULL
TI **Conjugate** vaccine for group B streptococcus
IN Michel, James L., Waban, MA, United States
Kasper, Dennis L., Newton Centre, MA, United States
Ausubel, Frederick M., Newton, MA, United States
Madoff, Lawrence C., Boston, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5908629 19990601
AI US 1995-467147 19950606 (8)
RLI Division of Ser. No. US 1994-363311, filed on 22 Dec 1994, now patented, Pat. No. US 5648241 which is a continuation of Ser. No. US 1992-968866, filed on 2 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408036, filed on 15 Sep 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.

LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.
CLMN Number of Claims: 21
ECL Exemplary Claim: 2
DRWN 14 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 3278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 52 OF 64 USPATFULL

AB This invention relates to treatment of traveller's diarrhea, including diarrhea caused by enterotoxigenic Escherichia coli (ETEC), using an oligosaccharide-containing composition. The composition contains an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm. The oligosaccharide-containing composition binds E. coli heat-labile toxin (LT). More specifically, the invention concerns neutralization and removal of LT associated with traveller's diarrhea.

AN 1999:43605 USPATFULL

TI Treatment of traveller's diarrhea

IN Heerze, Louis D., Alberta, Canada
Armstrong, Glen D., Alberta, Canada

PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)

PI US 5891860 19990406

WO 9639189 19961212

AI US 1998-973443 19980416 (8)

WO 1996-CA144 19960311

19980416 PCT 371 date

19980416 PCT 102(e) date

DT Utility

FS Granted

EXNAM Primary Examiner: Lee, Howard C.

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 5 Drawing Figure(s); 5 Drawing Page(s)

LN.CNT 1146

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 53 OF 64 USPATFULL

AB This invention relates to treatment of cholera and related conditions using oligosaccharide compositions which bind V. cholerae toxin and/or one or more serotypes of the organism V. cholerae. More specifically, the invention concerns neutralization and removal of V. cholerae toxin and/or organisms from the intestinal tract.

AN 1998:115724 USPATFULL

TI Treatment of cholera

IN Heerze, Louis D., Edmonton, Canada
Armstrong, Glen D., Edmonton, Canada

PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)

PI US 5811409 19980922

AI US 4608933 19950605 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Peselev, Elli

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 9 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 1292

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 54 OF 64 USPATFULL

AB A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus

polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such **polysaccharide**-protein unit or may contain a mixture of more than one type of unit.

AN 1998:154381 USPTAFULL
TI **Conjugate** vaccine for group B Streptococcus
IN Michel, James L., Waban, MA, United States
Kasper, Dennis L., Newton Centre, MA, United States
Ausubel, Frederick M., Newton, MA, United States
Madoff, Lawrence C., Boston, MA, United States
PA The General Hospital Corp., Charlestown, MA, United States (U.S. corporation)
The Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5847081 19981208
AI US 1995-462679 19950605 (8)
RLI Division of Ser. No. US 1994-363311, filed on 22 Dec 1994, now patented, Pat. No. US 5648241 which is a continuation of Ser. No. US 1992-968866, filed on 2 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408036, filed on 15 Sep 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 5
DRWN 14 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 3048
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 55 OF 64 USPTAFULL

AB A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides **polysaccharide**-protein moieties and contain (a) a group B Streptococcus **polysaccharide conjugated** to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such **polysaccharide**-protein unit or may contain a mixture of more than one type of unit.
AN 1998:150465 USPTAFULL
TI **Conjugate** vaccine for group B streptococcus
IN Michel, James L., Waban, MA, United States
Kasper, Dennis L., Newton, MA, United States
Ausubel, Frederick M., Newton, MA, United States
Madoff, Lawrence C., Boston, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5843444 19981201
AI US 1995-470445 19950606 (8)
RLI Division of Ser. No. US 1994-363311, filed on 22 Dec 1994, now patented, Pat. No. US 5648241 which is a continuation of Ser. No. US 1992-968866, filed on 2 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408036, filed on 15 Sep 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 3183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 56 OF 64 USPATFULL

AB A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides **polysaccharide** -protein moieties and contain (a) a group B Streptococcus **polysaccharide conjugated** to (b)) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such **polysaccharide**-protein unit or may contain a mixture of more than one type of unit.

AN 1998:124194 USPATFULL

TI **Conjugate** vaccine for group B streptococcus

IN Michel, James L., Waban, MA, United States
Kasper, Dennis L., Newton Centre, MA, United States
Ausubel, Frederick M., Newton, MA, United States
Madoff, Lawrence C., Boston, MA, United States

PA The General Hospital Corp., Charlestown, MA, United States (U.S. corporation)
The Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

PI US 5820860 19981013

AI US 1995-463288 19950605 (8)

RLI Division of Ser. No. US 1994-363311, filed on 22 Dec 1994, now patented, Pat. No. US 5648241 which is a continuation of Ser. No. US 1992-968866, filed on 2 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408036, filed on 15 Sep 1989, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Brusca, John S.

LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 3234

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 57 OF 64 USPATFULL

AB This invention relates to treatment of cholera and related conditions using oligosaccharide compositions which bind V. cholerae toxin and/or one or more serotypes of the organism V. cholerae. More specifically, the invention concerns neutralization and removal of V. cholerae toxin and/or organisms from the intestinal tract.

AN 1998:122384 USPATFULL

TI Treatment of cholera

IN Heerze, Louis D., Edmonton, Canada
Armstrong, Glen D., Edmonton, Canada

PA Synsorb Biotech, Inc., Canada (non-U.S. corporation)

PI US 5817633 19981006

AI US 1996-678059 19960709 (8)

RLI Continuation of Ser. No. US 1995-460893, filed on 5 Jun 1995

DT Utility

FS Granted

EXNAM Primary Examiner: Peselev, Elli

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 11 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 1160

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 58 OF 64 USPATFULL

AB This invention relates to treatment of cholera and related conditions using oligosaccharide compositions which bind V. cholerae toxin and/or one or more serotypes of the organism V. cholerae. More specifically, the invention concerns neutralization and removal of V. cholerae toxin and/or organisms from the intestinal tract.

AN 97:76113 USPATFULL

TI Treatment of cholera

IN Heerze, Louis D., Edmonton, Canada

Armstrong, Glen D., Edmonton, Canada

PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)

PI US 5661131 19970826

AI US 1995-442457 19950605 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Jordan, Kimberln R.

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 9 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 1273

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 59 OF 64 USPATFULL

AB A purified DNA molecule is disclosed that comprises a DNA sequence encoding a Group B Streptococcus alpha antigen or antibody eliciting fragment. The alpha antigen sequence encodes several distinct domains including an N-terminal sequence that precedes the start of the alpha antigen repeating sequence, a C-terminal anchor sequence and a repeating unit motif. The ability to protect mice against a Streptococcus infection with antisera against cellular extracts containing the alpha antigen encoded by the DNA molecule was determined.

AN 97:61577 USPATFULL

TI **Conjugate** vaccine against group B streptococcus

IN Michel, James L., Waban, MA, United States

Kasper, Dennis L., Newton Centre, MA, United States

Ausubel, Frederick M., Newton, MA, United States

Madoff, Lawrence C., Boston, MA, United States

PA The General Hospital Corporation, Charlestown, MA, United States (U.S. corporation)

Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

PI US 5648241 19970715

AI US 1994-363311 19941222 (8)

RLI Continuation of Ser. No. US 1992-968866, filed on 2 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408036, filed on 15 Sep 1989, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.

LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 2876

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 60 OF 64 USPATFULL

AB This invention relates to treatment of traveller's diarrhea, including diarrhea caused by enterotoxogenic Escherichia coli (ETEC), using an oligosaccharide-containing composition. The composition contains an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm. The oligosaccharide-containing composition binds E. coli

heat-labile toxin (LT). More specifically, the invention concerns neutralization and removal of LT associated with traveller's diarrhea.

AN 97:49626 USPATFULL
TI Treatment of traveller's diarrhea
IN Heerze, Louis D., Edmonton, Canada
Armstrong, Glen D., Edmonton, Canada
PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)
PI US 5637576 19970610
AI US 1995-461625 19950605 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Wilson, James O.
LREP Burns, Doane, Swecker & Mathis L.L.P.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1122
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 61 OF 64 USPATFULL

AB This invention relates to treatment of antibiotic associated diarrhea, including **Clostridium difficile** associated diarrhea (CDAD) and pseudomembranous colitis (PMC), using oligosaccharide compositions which bind C. difficile **toxin A**. More specifically, the invention concerns neutralization of C. difficile **toxin A** associated with CDAD.

AN 97:47510 USPATFULL
TI Method of binding and removing **toxin A**
IN Heerze, Louis D., Edmonton, Canada
Armstrong, Glen D., Edmonton, Canada
PA Synsorb, Biotech Inc., Alberta, Canada (non-U.S. corporation)
PI US 5635606 19970603
AI US 1995-450572 19950525 (8)
RLI Continuation of Ser. No. US 1994-195009, filed on 14 Feb 1994, now patented, Pat. No. US 5484773
DT Utility
FS Granted
EXNAM Primary Examiner: Peselev, Elli
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 62 OF 64 USPATFULL

AB This invention relates to treatment of traveller's diarrhea, including diarrhea caused by enterotoxigenic Escherichia coli (ETEC) which treatment uses an oligosaccharide-containing composition. The composition contains an oligosaccharide sequence covalently attached to a pharmaceutically acceptable solid, inert support through a non-peptidyl compatible linker arm. The oligosaccharide-containing composition binds E. coli heat-labile toxin (LT) and/or one or more serotypes of enterotoxigenic E. coli organisms. More specifically, the invention relates to prevention of ETEC from colonizing the intestinal tract and inducing disease. This invention also concerns neutralization and removal of LT associated with traveller's diarrhea.

AN 97:38506 USPATFULL
TI Treatment of traveller's diarrhea
IN Heerze, Louis D., Edmonton, Canada
Armstrong, Glen D., Edmonton, Canada
PA Synsorb Biotech, Inc., Calgary, Canada (non-U.S. corporation)
PI US 5627163 19970506
AI US 1995-461294 19950605 (8)

DT Utility
FS Granted
EXNAM Primary Examiner: Wilson, James O.
LREP Burns, Doane, Swecker & Mathis L.L.P.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1153
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 63 OF 64 USPATFULL
AB This invention relates to treatment of antibiotic associated diarrhea, including **Clostridium difficile** associated diarrhea (CDAD) and pseudomembranous colitis (PMC), using oligosaccharide compositions which bind C. difficile **toxin A**. More specifically, the invention concerns neutralization of C. difficile **toxin A** associated with CDAD.
AN 96:5776 USPATFULL
TI Treatment of antibiotic associated diarrhea
IN Heerze, Louis D., Edmonton, Canada
Armstrong, Glen D., Edmonton, Canada
PA Alberta Research Council, Edmonton, Canada (non-U.S. corporation)
PI US 5484773 19960116
AI US 1994-195009 19940214 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Burns, Doane, Swecker & Mathis, Swiss, Gerald F., Dillahunty, Mary Ann
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 64 OF 64 USPATFULL
AB The production of stable hybrid cell lines that secrete human monoclonal antibodies against bacterial toxins by fusing post-immunization human peripheral blood lymphocytes with nonsecretor mouse myeloma cells is described. Using the method, protective monoclonal antibodies against tetanus toxin and diphtheria toxin were produced that bind tetanus toxin and diphtheria toxin in vitro, respectively, and prevent tetanus and diphtheria in vivo in animals, respectively.
AN 87:60237 USPATFULL
TI Human monoclonal antibodies against bacterial toxins
IN Insel, Richard A., Rochester, NY, United States
Gigliotti, Francis, Memphis, TN, United States
PA University of Rochester, Rochester, NY, United States (U.S. corporation)
PI US 4689299 19870825
AI US 1983-534658 19830922 (6)
RLI Continuation-in-part of Ser. No. US 1982-428747, filed on 30 Sep 1982, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Hazel, Blondel
LREP Pennie & Edmonds
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.